• Eun Jin Ahn, Hyun Kang, Geun Joo Choi, Chong Wha Baek, Yong Hun Jung, and Young Choel Woo.
• From the Department of Anaesthesiology and Pain Medicine, Inje University, Seoul Paik Hospital, Seoul, Korea; and Department of Anaesthesiology and Pain Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
• Anesth. Analg. 2016 Mar 1; 122 (3): 664-676.

BackgroundPrevious randomized controlled trials regarding the effectiveness of perioperative midazolam in preventing postoperative nausea and vomiting (PONV) have produced conflicting results. Consequently, the present systematic review was performed to assess the effect of perioperative administration of midazolam on PONV.MethodsThe MEDLINE®, Embase, and Cochrane Central Register of Controlled Trials databases were searched to identify all randomized controlled trials that investigated the effectiveness of midazolam under general anesthesia. The primary end points were defined as postoperative nausea (PON), postoperative vomiting (POV), and PONV.ResultsFrom 16 studies, 1433 patients were included in the final analysis. Compared with the control group, patients who received midazolam showed a lower overall incidence of PON (risk ratio [RR], 0.51; 95% confidence interval [CI], 0.40-0.65; I = 35%; number needed to treat [NNT] = 6; number of included studies [n] = 11), POV (RR, 0.46; 95% CI, 0.33-0.65; I = 0%; NNT = 8; n = 10), and PONV (RR, 0.45; 95% CI, 0.36-0.57; I = 31%; NNT = 3; n = 7).ConclusionsPerioperative administration of midazolam was effective in preventing PON, POV, and PONV.

11 keywords...

hide…